Xenetic Biosciences (XBIO) Expected to Announce Quarterly Earnings on Tuesday

Posted by Nicole Kennedy on Nov 4th, 2025

Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) is projected to post its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter. Investors may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, November 12, 2025 at 7:00 AM ET.

Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.19. The company had revenue of $0.59 million for the quarter, compared to analysts’ expectations of $0.48 million. Xenetic Biosciences had a negative return on equity of 54.56% and a negative net margin of 126.08%. On average, analysts expect Xenetic Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Xenetic Biosciences Price Performance

XBIO stock traded down $0.08 during mid-day trading on Tuesday, reaching $3.05. The company had a trading volume of 25,121 shares, compared to its average volume of 276,335. The firm has a 50 day moving average of $3.76 and a 200 day moving average of $3.37. Xenetic Biosciences has a 12 month low of $2.20 and a 12 month high of $13.93. The company has a market capitalization of $4.69 million, a PE ratio of -1.52 and a beta of 2.44.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenetic Biosciences in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Reduce”.

Get Our Latest Analysis on XBIO

About Xenetic Biosciences

(Get Free Report)

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.